Endogenous Urotensin II Selectively Modulates Erectile Function through eNOS

Roberta d’Emmanuele di Villa Bianca1,2, Emma Mitidieri2, Ferdinando Fusco1, Elena D’Aiuto3, Paolo Grieco4, Ettore Novellino4, Ciro Imbimbo1, Vincenzo Mirone1, Giuseppe Cirino1,2, Raffaella Sorrentino1,2*

1 Interdepartmental Research Centre for Sexual Medicine (CIRMS), University of Naples, Federico II, Naples, Italy, 2 Department of Experimental Pharmacology, University of Naples, Federico II, Naples, Italy, 3 Section of Clinical Immunology, Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy, 4 Department of Pharmaceutical and Toxicological Chemistry, University of Naples, Federico II, Naples, Italy

Abstract

Background: Urotensin II (U-II) is a cyclic peptide originally isolated from the neurosecretory system of the teleost fish and subsequently found in other species, including man. U-II was identified as the natural ligand of a G-protein coupled receptor, namely UT receptor. U-II and UT receptor are expressed in a variety of peripheral organs and especially in cardiovascular tissue. Recent evidence indicates the involvement of U-II/UT pathway in penile function in human, but the molecular mechanism is still unclear. On these bases the aim of this study is to investigate the mechanism(s) of U-II-induced relaxation in human corpus cavernosum and its relationship with L-arginine/Nitric oxide (NO) pathway.

Methodology/Principal Findings: Human corpus cavernosum tissue was obtained following in male-to-female transsexuals undergoing surgical procedure for sex reassignment. Quantitative RT-PCR clearly demonstrated the U-II expression in human corpus cavernosum. U-II (0.1 nM–10 μM) challenge in human corpus cavernosum induced a significant increase in NO production as revealed by fluorometric analysis. NO generation was coupled to a marked increase in the ratio eNOS phosphorylated/eNOS as determined by western blot analysis. A functional study in human corpus cavernosum strips was performed to assess eNOS involvement in U-II-induced relaxation by using a pharmacological modulation. Pre-treatment with both wortmannin or geldanamycinin (inhibitors of eNOS phosphorylation and heat shock protein 90 recruitment, respectively) significantly reduced U-II-induced relaxation (0.1 nM–10 μM) in human corpus cavernosum strips. Finally, a co-immunoprecipitation study demonstrated that UT receptor and eNOS co-immunoprecipitate following U-II challenge of human corpus cavernosum tissue.

Conclusion/Significance: U-II is endogenously synthesized and locally released in human corpus cavernosum. U-II elicited penile erection through eNOS activation. Thus, U-II/UT pathway may represent a novel therapeutical target in erectile dysfunction.

Introduction

Urotensin II (U-II) is a cyclic peptide hormone derived from pre-pro-U-II by urotensin-converting enzyme. It was first isolated from teleost fish and homologues subsequently were identified across the evolutionary spectrum, including mammals and man. U-II causes both vasoconstriction and vasodilation depending by the vascular district and the species considered [1–6]. Its vasoactive effect is mediated by binding to a GPR14 (UT receptor), a G protein-coupled receptor [7]. U-II is secreted from heart and several other tissues into the circulation [8]. However, the source of U-II production in the human body remains to be elucidated. Both U-II and UT receptor are expressed widely within the cardiovascular system, and their expression is up-regulated in human cardiovascular disease, including congestive heart failure, hypertension, type II diabetes and diabetic nephropathy [9–11]. Collectively, these data indicate U-II as potential modulator of cardiovascular homeostasis in human.

Recently, we have demonstrated the involvement of U-II/UT pathway in erectile function [12]. Indeed, an intra-cavernous injection of U-II in rats causes an increase in intra-cavernous pressure without affecting systemic blood pressure. It has also been demonstrated that UT receptor is present in human corpus cavernosum (HCC). It is located on the endothelium and it mediates an endothelium-dependent relaxation involving the L-arginine/nitric oxide (NO) pathway [12]. It is well established that the L-arginine/NO pathway plays a major role in erectile function in man [13,14]. NO is produced by a group of enzymes called nitric oxide synthase (NOS) that by converting L-arginine into L-citrulline produce NO [15,16]. The endothelial NOS (eNOS) is...
constitutively expressed within the vascular system, it is tightly regulated and produces physiologically relevant levels of NO.

The regulation of eNOS involves multiple molecular mechanisms that act in concert to both positively or negatively affect the function of this enzyme. eNOS is classified as a constitutive and strictly calcium/calmodulin-dependent enzyme [17]. The calcium levels as well as the heat shock protein 90 (Hsp90) recruitment increase the catalytic activity of eNOS [18,19]. The eNOS-associated Hsp90 may also serve as a scaffolding protein, facilitating the organization of additional associated regulatory proteins. In addition, fluid shear stress or other stimuli by phosphorylation can shift eNOS to an higher state of activation [20]. For example, bradykinin enhances eNOS phosphorylation; this effect is maximal after 5 minutes and it is maintained for at least 20 minutes in cultured endothelial cells [21]. In recent years, it has been reported that eNOS phosphorylation at serine 1177 by phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt) is critical for the maintenance of full penile erection [22,23]. Thus eNOS activity is finely regulated and can shift to an higher degree of activation following molecular modulation [17–23].

The present study investigates the relationship between U-II/UT and L-arginine/NO pathway in human corpus cavernosum. Our data demonstrate that U-II pro-erectile response relies on eNOS-derived NO, contributing to the maintenance of full penile erection.

Results

U-II is present as mRNA in HCC

The RT-PCR analysis (Figure 1) clearly demonstrated the U-II presence in HCC samples. Since it has been reported that U-II is over-expressed in human tumoural cell lines SW-13 [24], a positive control by using SW-13 cells was performed, too. No amplifications were observed when PCR was performed in same conditions but without cDNA.

Taken together, these data demonstrate that U-II can be locally synthesized and endogenously released in HCC.

U-II vasorelaxant effect involves eNOS activation

As previously described U-II causes an endothelium- and NO-dependent relaxation in pre-contracted HCC strips [12]. A pharmacological eNOS modulation was operated by using inhibitors that either interfere with Hsp90 recruitment (geldanamycin) or inhibit phosphorylation (wortmannin). Both wortmannin (0.1 μM) or geldanamycin (1 μM) significantly reduced U-II induced relaxation of human tissues (Figure 2 A, ***p<0.001 and **p<0.01).

U-II promotes NO production in HCC

In order to confirm the NO involvement in U-II/UT signaling we evaluated the NO production in HCC homogenate tissues stimulated with U-II (1 nM–10 μM). Data, expressed as total nitrite, clearly showed that U-II caused a significant increase in NOx production compared with vehicle (Figure 2 B, *p<0.05, **p<0.01, ***p<0.001).

U-II induces eNOS phosphorylation in HCC

To further asses the U-II involvement in eNOS activation we performed a western blot study. The protein expression of eNOS as well as phosphorylated eNOSSer 1177 (p-eNOS) in tissues incubated with U-II (10 μM), at scheduled time, was evaluated. U-II induced eNOS phosphorylation in a time-dependent manner, reaching its maximum at 30 minutes (Figure 3 A, *p<0.05). Thus 30 minutes of incubation has been chosen as the time point to perform the experiments by using inhibitors. Wortmannin (0.1 μM), an irreversible inhibitor of PI3K, but not geldanamycin, reverted significantly eNOS phosphorylation induced by U-II challenge (**p<0.01, ***p<0.001, Figure 3 B).

U-II induces the recruitment of eNOS to UT receptor in HCC

The co-immunoprecipitation assay allows to identify protein-protein/enzyme interaction. Thus, to confirm the relation between U-II/UT pathway and eNOS, we performed the eNOS precipitation and monitored the co-precipitation of UT receptor in HCC tissues incubated for 30 minutes with U-II (10 μM) or vehicle. U-II induced the formation of the immunocomplex between UT and eNOS (Figure 4).

Discussion

Human penile erection is a resultant of several complex mechanisms. A key issue is the balance between contracting and relaxant factors which are instrumental in order to achieve penile erection. It is now well accepted that NO plays a major role in induction and maintenance of erection [25–28]. Recently we have reported that U-II-induced relaxation in HCC is endothelium-and NO-dependent [12]. On this basis we have proposed that U-II, physiologically circulating in our body [8], contributes to penile homeostasis. Our present finding further extends the importance of this signaling pathway and confirms that endothelium is necessary.

We have demonstrated that mRNA for U-II is present in the human tissue. This finding indicates that U-II can be locally endogenously synthesized within the HCC and that U-II/UT pathway is involved within erection physiology. The exclusive presence of UT receptor on the endothelial cells in human penile tissue [12] further corroborates this concept. Based on this and our previous finding, we have hypothesized an interaction between UT receptor and eNOS at molecular level within the endothelium. Following this hypothesis we performed a co-immunoprecipitation study. The formation of the immunocomplex demonstrated that a link exists between eNOS and U-II/UT pathway within the human penile tissue. This molecular evidence was functionally confirmed. Indeed, the incubation of HCC homogenates with U-II caused a concentration-dependent increase in NOX production.

Figure 1. Quantitative RT-PCR for U-II in HCC. U-II is expressed as mRNA in HCC samples. Human tumoural cells SW-13 were used as positive control. Data were normalized on the basis of GAPDH and expressed as mean ± standard error of the mean (SEM) of three different human specimens. doi:10.1371/journal.pone.0031019.g001
Interestingly, the highest U-II concentration elicited a six fold increase in NOx generation. Thus, U-II released within the corpus cavernosum binds its receptor on endothelial cells leading to eNOS activation and in turn to NO production. Basically, U-II-induced relaxation contributes to eNOS-derived NO generation in HCC. But how activation of this pathway leads to an increase production of eNOS-derived NO? To date it is well consolidate the concept that neuronal NOS (nNOS) and eNOS mediate the initiation and maintenance of penile erection, respectively [22]. Neuronal signal initiates penile erection by activating nNOS that elicits a rapid and transient NO release causing an increase in blood flow [29]. The resulting shear stress force on the endothelium activates the PI3K/Akt/eNOS phosphorylation cascade, causing more sustained NO release and relaxation [22,30]. Indeed, Akt-phosphorylated eNOS results 15 to 20 fold more active that un-phosphorylated eNOS [31]. In other words, the phosphorylation of eNOS shifts the enzyme at higher state of activation, boosting NO production [32].

In the human body, the penis is one of the organ physiologically subjected to shear stress and the resultant eNOS phosphorylation \(^{Ser1177}\) plays a key role in the maintenance of full penile erection [22]. Therefore, we performed a pharmacological modulation of the eNOS phosphorylation in order to investigate if U-II activity relies on this mechanism. U-II caused a significant increase in eNOS phosphorylation \(^{Ser1177}\) in a time-dependent manner. The irreversible inhibition of PI3K/Akt operated by wortmannin, reverted the phosphorylation induced by U-II. Also in this case the molecular finding has been confirmed through a

Figure 2. Panel A: U-II induced concentration-response curve (0.1 nM–10 \(\mu\)M) in HCC strips was significantly inhibited by pre-treatment with wortmannin (0.1 \(\mu\)M), PI3K inhibitor, or geldanamycin (1 \(\mu\)M) Hsp90 inhibitor (**p<0.001 and ***p<0.01 versus vehicle). Data were expressed as the mean \(\pm\) standard error of the mean (SEM) of six different specimens. Data were analyzed by ANOVA followed by Bonferroni post test. Panel B: NOx (total nitrite) production in HCC tissue incubated with U-II (1 nM-10 \(\mu\)M) or vehicle for 30 min. U-II caused a significant increase in NO production compared with vehicle (*p<0.05, **p<0.01, ***p<0.001). Data were expressed as mean \(\pm\) standard error of the mean (SEM) from four different specimens and analyzed by ANOVA followed by Bonferroni post test. doi:10.1371/journal.pone.0031019.g002

Figure 3. Western blot analysis for eNOS and p-eNOS\(^{Ser1177}\) in HCC tissue. Panel A: U-II (10 \(\mu\)M) caused an increase in eNOS phosphorylation expressed as p-eNOS/eNOS ratio in a time-dependent manner (*p<0.05 vs vehicle). Panel B: U-II-induced eNOS phosphorylation (**p<0.01 vs vehicle), was significantly reverted by wortmannin (0.1 \(\mu\)M), PI3K inhibitor, (p<0.05 vs U-II) but not by geldanamicin (1 \(\mu\)M), Hsp90 inhibitor. Data were expressed as the mean \(\pm\) standard error of the mean (SEM) of four different specimens and were analyzed by ANOVA followed by Bonferroni post test. doi:10.1371/journal.pone.0031019.g003
Methods

Peptide

The human U-II was synthesized and purified at the Department of Pharmaceutical and Toxicological Chemistry of the University of Naples, Federico II. The peptide was obtained by solid-phase peptide synthesis as previously reported [36]. Purification was achieved using a semi-preparative reversed phase high-performance liquid chromatography (HPLC) C18 bonded silica column (Vydac 218TP1010). The Separations Group Inc., Hesperia, CA, USA). The purified peptide was 99% pure as determined by analytical reversed-phase HPLC. The correct molecular weight were confirmed by mass spectrometry and amino acid analysis.

Human Tissue

In male-to-female transsexuals undergoing surgical procedure for sex reassignment, the penis and testicles were amputated and a neo-vagina was created to simulate female external genitalia. All the surgical procedures were performed at the Department of Urology, University of Naples, Federico II, Naples, Italy [37]. The corpora cavernosa were carefully excised from the penis immediately after amputation and placed in ice-cold oxygenated Krebs’ solution [37]. All patients were informed of all procedures and gave their written consent. Local Ethical Committee (Faculty of Medicine and Surgery; University of Naples Federico II, via Pansini, 5; 80131, Naples, Italy) approved the use of human corpus cavernous tissue for in vitro studies.

Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)

The presence of U-II was determined by quantitative PCR. Briefly, total RNA from omogenated HCC tissue was extracted by using TRIzol reagent (Invitrogen, Milan, Italy), to eliminate genomic DNA contamination 1 µg of above RNA was treated with RNase-free DNase I (Promega Corporation, Madison, USA), according to the manufacturer’s recommendations. Reverse transcription was performed using M-MLV Reverse Transcriptase (Invitrogen, Milan, Italy) according to the manufacturer’s recommendations, and 20 ng of cDNA samples were used for quantitative PCR. Samples were run in triplicate in 25-µL reactions using an 7500 Real Time PCR System (Applied Biosystems, Foster City, CA). Amplification was done using Sybr Green Master Mix (Applied Biosystems, Monza, Italy). U-II-specific forward primers 5’-GCACCTGTTTTGGACCTCG-3’ and reverse primer : 5’-TGGTCGTCCATGCACAGATT-3’, and human GAPDH forward primer 5’-AACCGATTTTGGTCGATTGCGG- 3’ and reverse primer 5’-TGGTCCTGGAA-GATGGGTAG-3’ were specifically designed using Primer Express Software 2.0 and validated for their specificity. Samples were incubated at 30°C for 2 min and at 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C for 1 min.

Differences in cDNA input were corrected by normalizing signals obtained with primers specific for glyceraldehydes-3-phosphate dehydrogenase (GAPDH). To exclude nonspecific amplification and/or the formation of primer dimers, control reactions were performed in the absence of target cDNA. In order to validate the results we used human tumoral cell lines SW-13 as positive control [24]. Gene expression levels were calculated using the 2^(-ΔΔCT) method and are presented as ratio between mean fold change of target gene and GAPDH ± standard error. Data were expressed as mean ± standard error of the mean (SEM) from three different specimens.

NOx determination

HCC tissues were incubated with U-II at different concentration (1 nM–10 µM) or vehicle for 30 minutes at 37°C. The reaction was stopped in liquid nitrogen. Homogenate tissues were incubated in a microplate with cadmium (50 mg/well) for 1 h to convert the inorganic anions nitrate (NO3) to nitrite (NO2). After centrifugation at 14,000 rpm for 15 min, total nitrite (NOx)...
content was determined fluorometrically in microtiter plates (PerkinElmer Instruments, LS55; UK) using a standard curve of sodium nitrite [38]. NOx content was calculated by using the internal standard curve. Data were expressed as mean ± standard error of the mean (SEM) from four different specimens and analyzed by using analysis of variance (ANOVA) followed by Bonferroni post hoc test. The level of statistical significance was taken as *p*<0.05.

**Functional reactivity of HCC Strips**

Longitudinal strips (2 cm) of HCC were dissected and isolated from the trabecular structure of the penis [25]. Krebs’ solution had the following composition (mM): 115.3 NaCl; 4.9 KCl; 1.46 CaCl2; 1.2 MgSO4; 1.2 KH2PO4; 25.0 NaHCO3; 11.1 glucose (Carlo Erba, Milan, Italy). HCC strips were mounted in organ bath containing oxygenated (95% O2 and 5% CO2) Krebs’ solution at 37°C. HCC strips were connected to isometric force-displacement transducers (model 7002, Ugo Basile, Comerio, Italy) and changes in tension were recorded continuously by using a software (Datacapsule, Basile, Comerio, Italy). Tissues were preloaded with 2 g of tension and allowed to equilibrate for 90 minutes in Krebs’ solution. After equilibration, tissues were standardized by performing repeated phenylephrine (PE; 3 μM; Sigma, Milan, Italy) contractions until three equal responses were treated with wortmannin (0.1 μM, Sigma, Milan, Italy). HCC strips were incubated in organ bath for 30 minutes with or without endothelium, using HCC strips pre-contracted with PE (3 μM). In order to investigate the involvement of L-arginine/NO pathway in U-II-induced relaxation we operated a pharmacological modulation. HCC strips were incubated for 30 minutes with either wortmannin (0.1 μM, Tocris, UK) or geldanamycin (1 μM, Sigma, Milan, Italy) or Hsp90 inhibitor before U-II challenge. The doses of wortmannin (0.1 μM) and geldanamycin (1 μM) were selected by a preliminary dose–finding study (data not shown).

Data were calculated as % of relaxation to PE tone and expressed as the mean ± standard error of the mean (SEM) of six different specimens. The results were analyzed by using analysis of variance (ANOVA) followed by Bonferroni post hoc test. The level of statistical significance was taken as *p*<0.05.

**Western Blot Analysis**

In order to evaluate the effect of U-II on the eNOS phosphorylation -Ser 1177 (p-eNOS Ser-1177), HCC tissues were incubated with the peptide (10 μM) at scheduled time (5, 15, 30 and 60 minutes). In another set of experiments, tissues were pre-treated with wortmannin (0.1 μM, Tocris, UK) or geldanamycin (1 μM, Sigma, Milan, Italy) and thereafter incubated with U-II (10 μM) or vehicle for 30 minutes. Next, HCC tissues were homogenized in modified RIPA buffer (Tris-HCl 50 mM, pH 7.4, Triton 1%, sodium deoxycholate 0.25%, NaCl 150 mM, ethylenediaminetetraacetic acid 1 mM, phenylmethylsulphonyl fluoride 1 mM, aprotinin 10 μg/mL, leupeptin 20 μg/mL, NaF 1 μM, sodium orthovanadate 1 μM) by liquid nitrogen. Protein concentration was estimated by the Bio-Rad protein assay using bovine serum albumin (BSA) as standard. Equal amounts of protein (50 μg) of the tissue lysates were separated on 8% sodium dodecyl sulfate polyacrylamide gels and transferred to a polyvinylidene fluoride membrane. Membranes were blocked by incubation in phosphate-buffered saline (PBS) containing 0.1% v/v Tween 20, non fat dry milk (5%) and NaF (50 mM) for 1 hour, followed by overnight incubation at 4°C with rabbit anti-p-eNOS (Ser-1177) polyclonal antibody (1:1000, Cell Signaling, DBA, Italy) and with mouse eNOS monoclonal antibody (1:1000; BD Transduction Laboratories). The filters were washed extensively in PBS containing 0.1% v/v Tween 20, before incubation for 2 hours with horseradish peroxidase-conjugate anti rabbit secondary antibody (1:5000). Membranes were then washed and developed using enhanced chemiluminescence substrate (Amer sham Pharmacia Biotech, San Diego, CA, USA). The data were evaluated by densitometric analysis and expressed as p-eNOS/ eNOS ratio.

Data were expressed as mean ± standard error of the mean (SEM) of four different specimens. The results were analyzed by using analysis of variance (ANOVA) followed by Bonferroni post hoc test. The level of statistical significance was taken as *p*<0.05.

**UT receptor and eNOS co-immunoprecipitation**

HCC samples were homogenized (500 μg) and incubated with 20 μl of Protein A-coupled sepharose beads and 1 μg/mL of IgG mouse at 4°C for 3 h. The samples were centrifuged (600 rpm for 15 sec) and the supernatants were incubated overnight at 4°C with 20 μl of mouse eNOS monoclonal antibody (Cell Signaling, DBA, Milan, Italy) or normal mouse serum (to evaluate non-specific binding) on a rotating wheel. Next, the samples were incubated with 40 μl of Protein A-coupled sepharose beads at 4°C for 2 h and centrifuged (600 rpm for 15 sec). The pellets were extensively washed and then suspended in 3 x Laemmli buffer. After heating at 95°C for 5 minutes, samples were subjected to Western blot analysis developed for UT (1:1000; GPR14 (H-90), Santa Cruz Biotechnology Inc., Heidelberg, Germany).

**Author Contributions**

Conceived and designed the experiments: GC RddVB RS. Performed the experiments: ED RddVB FF PG CI EM. Analyzed the data: GC RddVB FF EM VM EN RS. Wrote the paper: GC RddVB RS.

**References**

1. Douglas SA, Ashton DJ, Sauermelch CF, Coateyn RW, Ohlstein DH, et al. (2000) Human urotensin-II is a potent vasoactive peptide: Pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 36(5 suppl 1): S163-166.
2. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, et al. (2000) Contractile responses to human urotensin-II in rat and human pulmonary arteries: Effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130: 201-204.
3. Rosowski WJ, Cheng BL, Taylor JE, Dutta R, Coy DH (2002) Human urotensin-II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: Inhibition by somatostatin receptor antagonists. Eur J Pharmacol 438: 159-170.
4. Bottrill FE, Douglas SA, Hiley CR, White R (2000) Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130: 1865-1870.
5. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, et al. (2001) Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280: H925-928.
6. Bohn F, Perron J (2002) Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 135: 25-27.
7. Romanic AM, Louden CS, Foley J, Sauermelch CF, Coateyn RW, et al. (1999) Human urotensin-II is a potent vasconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286.
8. Chen YH, Yandle TG, Richards AM, Palmer SG (2009) Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release. Clin Chem 55: 2040-2048.
9. Maquire JJ, Kac RE, Davenport AP (2000) Orphan-receptor ligand human urotensin II: Receptor localization in human tissues and comparison of vasconstrictor responses with endothelin-1. Br J Pharmacol 131: 441-446.
eNOS Involvement in U-II Induced Penile Erection

10. Zhu YC, Zhu YZ, Moore PK (2006) The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol 148: 884–901.

11. Russell FD (2004) Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther 103: 223–245.

12. d’Emmanuele di Villa Bianca R, Cirino G, Mitidieri E, Coletta C, Grassia G, et al. (2010) Urotensin II: a novel target in human corpus cavernosum. J Sex Med 7: 1778–1786.

13. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, et al. (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170: 843–850.

14. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH (1992) Nitric oxide: a physiologic mediator of penile erection. Science 257: 401–403.

15. Alderton WK, Cooper CE, Knowles RG (2001) Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593–613.

16. Nathan C, Xie QW (1994) Nitric oxide synthases: roles, tolls, and controls. Cell 78: 915–918.

17. Busse R, Müller A (1990) Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett 265: 133–136.

18. García-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, et al. (1998) Dynamic activation of dnt activation of the endothelial nitric oxide synthase in response to endothelial nitric oxide synthase by Hsp90. Nature 292: 821–824.

19. Russell KS, Haynes MP, Gaulin-Glaser T, Rosneck J, Sessa WC, et al. (2000) Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells. Effects on calcium sensitivity and NO release. J Biol Chem 275: 5026–5030.

20. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, et al. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 397–401.

21. Michel T, Li GK, Busconi L (1993) Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 90: 6252–6256.

22. Hurt KJ, Musicki B, Palese MA, Crone JC, Becker RE, et al. (2002) Akt-dependent phosphorylation of endothelial nitric oxide synthase mediates penile erection. Proc Natl Acad Sci U S A 99: 4061–4066.

23. d’Emmanuele di Villa Bianca R, Sorrentino R, Sorrentino R, Imbimbo G, Palmieri A, et al. (2006) Sphingosine 1-phosphate induces endothelial nitric-oxide synthase activation through phosphorylation in human corpus cavernosum. J Pharmacol Exp Ther 316: 783–790.

24. Takahashi K, Totsumi K, Murakami O, Shibaaraa S (2003) Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adenocortical carcinoma cells. Peptides 22: 1175–1179.

25. Burnett AL (2004) Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 16(Suppl 1): S15–19.

26. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH (1992) Nitric oxide: a physiologic mediator of penile erection. Science 257: 401–403.

27. Toda N, Ayajiki K, Okamura T (2003) Nitric oxide and penile erectile function. Pharmacol Ther 106: 233–266.

28. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170: 843–850.

29. Burnett AL, Tillman SL, Chang TS, Epstein JL, Lowenstein CJ, et al. (1993) Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. J Urol 150: 73–76.

30. Dinnmeler S, Fleming I, Fischhalter B, Herrmann C, Russe R, et al. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601–605.

31. Galli B, Cothrels GL, Goodlett DR, Ueha H, Kim F, et al. (1999) Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. Biol Chem 274: 30101–30108.

32. Boo YC, Kim HJ, Song H, Fulton D, Sessa W, et al. (2006) Coordinated regulation of endothelial nitric oxide synthase activity by phosphorylation and subcellular localization. Free Radic Biol Med 41: 144–153.

33. Fulton D, Gratton JP, Sessa WC (2000) Post-translational control of endothelial nitric oxide synthase: why isn’t calcium/calmodulin enough? J Pharmacol Exp Ther 299: 818–824.

34. Gratton JP, Fontana J, O’Connor DS, Garcia-Cardenas G, McCabe TJ, et al. (2000) Reconstitution of an endothelial nitric-oxide synthase (eNOS), hsp90, and caveolin-1 complex in vitro. Evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1. J Biol Chem 275: 22269–22272.

35. McMahon CN, Smith CJ, Shabsigh R (2006) Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 332: 589–592.

36. Greco P, Carotenuto A, Campiglia P, Zampelli E, Patacchini R, et al. (2000) A new, potent urotensin II receptor peptide agonist containing a Pen residue at the diulidile bridge. J Med Chem 43: 4391–4394.

37. Mirone V, Sorrentino R, d’Emmanuele di Villa Bianca R, Imbimbo C, Palmieri A, et al. (2000) A standardized procedure for using human corpus cavernosum strips to evaluate drug activity. J Pharmacol Toxicol Methods 44: 477–482.

38. Misko TP, Schilling RJ, Salvemini D, Mooore WM, Carrie MG (1993) A fluorometric assay for the measurement of nitrite in biological samples. Analytical Biochemistry 214: 11–16.